CD8A and neoplasm: To date, the Immunoscore [11, 13] presents the most integrative approach to quantify the antitumoral immune reaction and this scoring has shown prognostic value for multiple entities – including CRC – considering expression of CD3 and CD8 at the tumour centre and at the invasive margin.